167 related articles for article (PubMed ID: 38385700)
1. Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections.
Cattaneo D; Fusi M; Galli L; Genovese C; Giorgi R; Matone M; Merli S; Colaneri M; Gori A
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0002324. PubMed ID: 38385700
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience.
Cattaneo D; Fusi M; Colaneri M; Fusetti C; Genovese C; Giorgi R; Matone M; Merli S; Petri F; Gori A
Antibiotics (Basel); 2023 Dec; 13(1):. PubMed ID: 38247579
[TBL] [Abstract][Full Text] [Related]
4. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
[TBL] [Abstract][Full Text] [Related]
5. A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections.
Gatti M; Viale P; Cojutti PG; Zamparini E; De Paolis M; Giannella M; Pea F; Tedeschi S
Int J Antimicrob Agents; 2023 May; 61(5):106773. PubMed ID: 36878410
[TBL] [Abstract][Full Text] [Related]
6. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
[TBL] [Abstract][Full Text] [Related]
7. A HPLC-DAD method to facilitate large-scale therapeutic drug monitoring of dalbavancin.
Destere A; Merino D; Bonesso L; Lavrut T; Bernasconni A; Garraffo R; Gérard AO; Drici MD
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 May; 1222():123694. PubMed ID: 37060815
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
[TBL] [Abstract][Full Text] [Related]
10. [Potential indications of dalbavancin in clinical practice].
Barberán J
Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():38-40. PubMed ID: 28129820
[TBL] [Abstract][Full Text] [Related]
11. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
[TBL] [Abstract][Full Text] [Related]
12. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round.
Corona A; Agarossi A; Veronese A; Cattaneo D; D'Avolio A
Ther Drug Monit; 2020 Apr; 42(2):165-168. PubMed ID: 32195987
[TBL] [Abstract][Full Text] [Related]
14. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
Gatti M; Andreoni M; Pea F; Viale P
Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of clinical evidence for dalbavancin].
Rodríguez-Pardo D
Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():33-37. PubMed ID: 28129819
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications.
Núñez-Núñez M; Casas-Hidalgo I; García-Fumero R; Vallejo-Rodríguez I; Anguita-Santos F; Hernández-Quero J; Cabeza-Barrera J; Ruiz-Sancho A
Eur J Hosp Pharm; 2020 Sep; 27(5):310-312. PubMed ID: 32839266
[TBL] [Abstract][Full Text] [Related]
17. Dalbavancin: a new lipoglycopeptide antibiotic.
Bailey J; Summers KM
Am J Health Syst Pharm; 2008 Apr; 65(7):599-610. PubMed ID: 18359966
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus.
Matesanz M; Poza A; Iñurrieta A; Fernández-Diaz E; Arroyo M; Domínguez I; Candel FJ
Rev Esp Quimioter; 2021 Aug; 34(4):396-399. PubMed ID: 33956412
[No Abstract] [Full Text] [Related]
19. Dalbavancin combined with linezolid in prosthetic-hip infection.
Carrión Madroñal IM; Sánchez Del Moral R; Abad Zamora JM; Martínez Marcos FJ
Rev Esp Quimioter; 2020 Apr; 33(2):147-148. PubMed ID: 32157859
[No Abstract] [Full Text] [Related]
20. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility.
Almangour TA; Perry GK; Terriff CM; Alhifany AA; Kaye KS
Diagn Microbiol Infect Dis; 2019 Mar; 93(3):213-218. PubMed ID: 30396697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
